NMA: Nonprescription Medicines Academy

New Product Alerts

August 29th, 2012

Syncol—the leading premenstrual and menstrual pain reliever in Mexico—soon will be available in the United States. Each Syncol caplet contains acetaminophen 500 mg, pamabrom 25 mg, and pyrilamine maleate 15 mg. Syncol will be marketed in bilingual packaging and promoted on Hispanic television networks in 2013.

Cold-EEZE Cold Remedy Daytime/Nighttime QuickMelts
The Cold-EEZE product line now includes Cold-EEZE Daytime/Nighttime QuickMelt tablets. The 18 Daytime QuickMelt tablets contain zinc gluconate to shorten the duration of common cold symptoms. The six Nighttime QuickMelt tablets are a combination product containing zinc gluconate, chamomile, and melatonin; they are formulated to shorten symptom duration and help patients fall asleep faster.

Dulcolax Laxative Tablets for Women
The Dulcolax product line has been extended to include Dulcolax Laxative Tablets for Women. Like regular Dulcolax Laxative Tablets, each enteric-coated tablet contains bisacodyl 5 mg. Dulcolax Laxative Tablets for Women are marketed in a pink box.

Nectresse Sweetener
McNeil Nutritionals, LLC—maker of Splenda (sucralose) sweeteners—has introduced Nectresse, a nonnutritive sweetener derived from monk fruit. Monk fruit extract is 150 times sweeter than table sugar (sucrose) and contributes zero calories to a serving of Nectresse. However, like other no-calorie sweeteners, Nectresse does include small amounts of other food ingredients (erythritol, sugar, and molasses) to provide needed volume and texture. In a meal plan for patients with diabetes, up to 2 packets or up to 1 teaspoon of Nectresse can considered a “free food” (i.e., a food that contains <20 calories and ≤5 g carbohydrate per serving).

Vascepa (icosapent ethyl)
The FDA has approved Vascepa (icosapent ethyl) capsules, a prescription product indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia (>500 mg/dL). Icosapent ethyl (formerly known as AMR101) is a patented, synthetic ethyl eicosapentaenoic acid (EPA). Vascepa is a purified marine-oil preparation consisting of “not less than 96%” EPA; Vascepa does not contain significant amounts of the other active omega-3 polyunsaturated fatty acid, docosahexaenoic acid (DHA). DHA is a major component of nonprescription fish-oil capsules as well as Lovaza, the first omega-3 polyunsaturated fatty acid (PUFA) preparation available by prescription only.